Literature DB >> 26403659

CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.

Fabrine Sales Massafera Tristão1,2,3, Márcio Lazzarini4, Sabine Martin4,5, Majid Amar1, Walter Stühmer4,5, Frank Kirchhoff6, Lucas Araújo Caldi Gomes4, Laurance Lanfumey7, Rui D Prediger8, Julia E Sepulveda1, Elaine A Del-Bel9,10, Rita Raisman-Vozari11.   

Abstract

Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons accompanied by an inflammatory reaction. The neuron-derived chemokine fractalkine (CX3CL1) is an exclusive ligand for the receptor CX3CR1 expressed on microglia. The CX3CL1/CX3CR1 signaling is important for sustaining microglial activity. Using a recently developed PD model, in which the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxin is delivered intranasally, we hypothesized that CX3CR1 could play a role in neurotoxicity and glial activation. For this, we used CX3CR1 knock-in mice and compared results with those obtained using the classical PD models through intraperitonal MPTP or intrastriatal 6-hydroxydopamine (6-OHDA). The striatum from all genotypes (CX3CR1(+/+), CX3CR1(+/GFP) and CX3CR1-deficient mice) showed a significant dopaminergic depletion after intranasal MPTP inoculation. In contrast to that, we could not see differences in the number of dopaminergic neurons in the substantia nigra of CX3CR1-deficient animals. Similarly, after 6-OHDA infusion, the CX3CR1 deletion decreased the amphetamine-induced turning behavior observed in CX3CR1(+/GFP) mice. After the 6-OHDA inoculation, a minor dopaminergic neuronal loss was observed in the substantia nigra from CX3CR1-deficient mice. Distinctly, a more extensive neuronal cell loss was observed in the substantia nigra after the intraperitoneal MPTP injection in CX3CR1 disrupted animals, corroborating previous results. Intranasal and intraperitoneal MPTP inoculation induced a similar microgliosis in CX3CR1-deficient mice but a dissimilar change in the astrocyte proliferation in the substantia nigra. Nigral astrocyte proliferation was observed only after intraperitoneal MPTP inoculation. In conclusion, intranasal MPTP and 6-OHDA lesion in CX3CR1-deficient mice yield no nigral dopaminergic neuron loss, linked to the absence of astroglial proliferation.

Entities:  

Keywords:  6-OHDA; Fractalkine (CX3CL1); Fractalkine receptor (CX3CR1); MPTP; Neurodegeneration; Neuroinflammation; Parkinson’s disease

Mesh:

Substances:

Year:  2015        PMID: 26403659     DOI: 10.1007/s12640-015-9557-5

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  84 in total

Review 1.  Epidemiology of neurodegeneration.

Authors:  Richard Mayeux
Journal:  Annu Rev Neurosci       Date:  2003-01-24       Impact factor: 12.449

Review 2.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

Review 3.  Physiology of microglia.

Authors:  Helmut Kettenmann; Uwe-Karsten Hanisch; Mami Noda; Alexei Verkhratsky
Journal:  Physiol Rev       Date:  2011-04       Impact factor: 37.312

4.  Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes.

Authors:  P P Michel; M Marien; M Ruberg; F Colpaert; Y Agid
Journal:  J Neurochem       Date:  1999-05       Impact factor: 5.372

5.  Generation and analysis of mice lacking the chemokine fractalkine.

Authors:  D N Cook; S C Chen; L M Sullivan; D J Manfra; M T Wiekowski; D M Prosser; G Vassileva; S A Lira
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

6.  Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.

Authors:  Krishnan Sriram; Joanna M Matheson; Stanley A Benkovic; Diane B Miller; Michael I Luster; James P O'Callaghan
Journal:  FASEB J       Date:  2002-07-18       Impact factor: 5.191

7.  The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease.

Authors:  Josh M Morganti; Kevin R Nash; Bethany A Grimmig; Sonali Ranjit; Brent Small; Paula C Bickford; Carmelina Gemma
Journal:  J Neurosci       Date:  2012-10-17       Impact factor: 6.167

8.  Prevention of dopaminergic neuronal death by cyclic AMP in mixed neuronal/glial mesencephalic cultures requires the repression of presumptive astrocytes.

Authors:  Sophie Mourlevat; Jean-Denis Troadec; Merle Ruberg; Patrick P Michel
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

9.  Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.

Authors:  Fabrine S M Tristão; Majid Amar; Ines Latrous; Elaine A Del-Bel; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-05-21       Impact factor: 3.911

10.  DAP12 and CD11b contribute to the microglial-induced death of dopaminergic neurons in vitro but not in vivo in the MPTP mouse model of Parkinson's disease.

Authors:  Kiyoka Kinugawa; Yann Monnet; Catherine Béchade; Daniel Alvarez-Fischer; Etienne C Hirsch; Alain Bessis; Stéphane Hunot
Journal:  J Neuroinflammation       Date:  2013-07-11       Impact factor: 8.322

View more
  5 in total

1.  Genetic Rescue Reverses Microglial Activation in Preclinical Models of Retinitis Pigmentosa.

Authors:  Lijuan Zhang; Xuan Cui; Ruben Jauregui; Karen Sophia Park; Sally Justus; Yi-Ting Tsai; Jimmy K Duong; Chun-Wei Hsu; Wen-Hsuan Wu; Christine L Xu; Chyuan-Sheng Lin; Stephen H Tsang
Journal:  Mol Ther       Date:  2018-06-21       Impact factor: 11.454

Review 2.  Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells.

Authors:  Francesca Garretti; Dritan Agalliu; Cecilia S Lindestam Arlehamn; Alessandro Sette; David Sulzer
Journal:  Front Immunol       Date:  2019-02-25       Impact factor: 7.561

Review 3.  The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders.

Authors:  Paulina Pawelec; Malgorzata Ziemka-Nalecz; Joanna Sypecka; Teresa Zalewska
Journal:  Cells       Date:  2020-10-13       Impact factor: 6.600

Review 4.  Microglia as Therapeutic Target for Radiation-Induced Brain Injury.

Authors:  Qun Liu; Yan Huang; Mengyun Duan; Qun Yang; Boxu Ren; Fengru Tang
Journal:  Int J Mol Sci       Date:  2022-07-27       Impact factor: 6.208

5.  Brain region-specific microglial and astrocytic activation in response to systemic lipopolysaccharides exposure.

Authors:  Edoardo Brandi; Laura Torres-Garcia; Alexander Svanbergsson; Caroline Haikal; Di Liu; Wen Li; Jia-Yi Li
Journal:  Front Aging Neurosci       Date:  2022-08-26       Impact factor: 5.702

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.